Immuneering (IMRX) reports 64% survival rate for Atebimetinib in pancreatic cancer trial, but shares plunge 23% as investors remain unconvinced about cross-trial comparisons and competitive threats.
Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.
New pancreatic cancer drug (atebimetinib + chemo) shows "extraordinary" results: 86% overall survival (OS) at 9 months, far exceeding the 47% standard of care. Pivotal trials planned for late 2025.
